Subcutaneous versus intravenous administration of Trastuzumab: a minimization cost analysis with real world data from a reference cancer centre in Peru.

Autor:	Otoya I; Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Perú.; https://orcid.org/0000-0001-6185-9853., Valdiviezo N; Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Perú.; https://orcid.org/0000-0002-4300-5958., Roque K; Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Perú.; Post Graduation Programme in Medicine, UNINOVE, Sao Paulo 03155-000, Brasil.; https://orcid.org/0000-0003-3267-7107., Morante Z; Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Perú.; https://orcid.org/0000-0003-2952-6068., Vidaurre T; Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Perú.; https://orcid.org/0000-0003-1995-4560., Neciosup SP; Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Perú.; https://orcid.org/0000-0002-2657-9853., Calderón MJ; Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Perú.; Institute of Investigations in Biomedical Sciences (INICIB), Universidad Ricardo Palma, Lima 15039, Perú.; https://orcid.org/0000-0003-4935-7927., Gomez HL; Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Perú.; Institute of Investigations in Biomedical Sciences (INICIB), Universidad Ricardo Palma, Lima 15039, Perú.; Oncosalud, Auna Ideas, Lima 15036, Perú.; https://orcid.org/0000-0003-2660-1843.
Jazyk:	angličtina
Zdroj:	Ecancermedicalscience [Ecancermedicalscience] 2024 May 31; Vol. 18, pp. 1708. Date of Electronic Publication: 2024 May 31 (Print Publication: 2024).
DOI:	10.3332/ecancer.2024.1708
Abstrakt:	Breast cancer (BC) is a global concern, with Peru experiencing a high incidence and mortality. Trastuzumab, a crucial treatment for human epidermal growth factor receptor 2-positive BC, is administered intravenously or subcutaneously (SC). This study evaluates the costs associated with both methods at Peru's Instituto Nacional de Enfermedades Neoplásicas. Real data indicate that SC administration reduces treatment costs by approximately S/15,049.09. Cross-continental comparisons highlight a global trend favouring SC administration for efficiency and cost-effectiveness. The analysis provides insights for informed decision-making in resource-constrained healthcare settings like Peru, emphasising the need to consider local contexts in optimising oncology care. Competing Interests: The authors declare that they have no conflict of interest. (© the authors; licensee ecancermedicalscience.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF